Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response

NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
 
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
 
Epigenomics also said it will use its proprietary OncoSign identification approach through a collaboration with its partner CellTrend for rapid identification of biomarkers in a panel of human tumor cell lines.
 
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.